The company has identified and patented a new class of proprietary ligands that share a pharmacological profile with psilocybin, which has shown promising clinical results in the treatment of depression.

Lophora holds a unique position in the market for Psychedelic therapies of the future.

Given our unique technology and knowledge of the field, we are confident that we are moving ahead of a global market shift towards Psychedelic Therapy as a treatment for various CNS disorders.